Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

December 3, 2024

Study Completion Date

January 1, 2025

Conditions

Efficacy and Safety

Interventions

DRUG

Arsenic trioxide Tablet +Fuzuloparib Capsules

Arsenic trioxide Tablet : 0.27\*9 tid po consecutive 21 days with 1 week rest． Fuzuloparib Capsules: 150 mg bid po

Trial Locations (1)

RECRUITING

Women's Hospital School Of Medicine Zhejiang University, Zhejiang

All Listed Sponsors

lead

Xing Xie

OTHER